Replagal
Phase 3Biologic
TakedaReplagal is one of 21 biologic programs targeting Fabry Disease. It is currently in Phase 3.
1
Indications
11
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Fabry Disease
#DrugCompanyPhaseTrials
1Fabrazyme (agalsidase Beta)
SanofiApproved
Venglustat
SanofiPhase 3
Active Comparator
ModernaPhase 3
Agalsidase
SanofiApproved
Farxiga
AstraZenecaPhase 2
Recombinant Alpha-Galactosidase a
AAssistance Publique - Hôpitaux de Paris
Approved
Galafold
AAmicus Therapeutics
Phase 3
Agalsidase Alfa
TakedaPhase 3
Migalastat Hcl
AAmicus Therapeutics
Phase 3
Replagal
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Fabry Disease11 trials
Alternative Dosing and Regimen of Replagal to Treat Fabry Disease
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00075244·25 enrolled
Show 8 more trials
An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00071877·25 enrolled
Replagal Enzyme Replacement Therapy for Adults With Fabry Disease
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 4·NCT00097890·25 enrolled
Dosing Study of Replagal in Patients With Fabry Disease
Completed·—·Phase 2·NCT00068107·13 enrolled
An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT00357786·3 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Replagal. EMBL-EBI & Wellcome Sanger Institute.
- [4]